DNA Link, Inc.

KOSDAQ:A127120 Rapporto sulle azioni

Cap. di mercato: ₩76.9b

DNA Link Performance dei guadagni passati

Il passato criteri di controllo 0/6

DNA Link has been growing earnings at an average annual rate of 14.8%, while the Biotechs industry saw earnings growing at 7.2% annually. Revenues have been growing at an average rate of 7.1% per year.

Informazioni chiave

14.8%

Tasso di crescita degli utili

24.4%

Tasso di crescita dell'EPS

Biotechs Crescita del settore11.7%
Tasso di crescita dei ricavi7.1%
Rendimento del capitale proprio-29.4%
Margine netto-36.3%
Ultimo aggiornamento sui guadagni30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

DNA Link, Inc. (KOSDAQ:127120) Shares Fly 27% But Investors Aren't Buying For Growth

Jul 12
DNA Link, Inc. (KOSDAQ:127120) Shares Fly 27% But Investors Aren't Buying For Growth

There Is A Reason DNA Link, Inc.'s (KOSDAQ:127120) Price Is Undemanding

Mar 19
There Is A Reason DNA Link, Inc.'s (KOSDAQ:127120) Price Is Undemanding

Is DNA Link (KOSDAQ:127120) Using Too Much Debt?

Apr 19
Is DNA Link (KOSDAQ:127120) Using Too Much Debt?

Introducing DNA Link (KOSDAQ:127120), A Stock That Climbed 61% In The Last Year

Feb 23
Introducing DNA Link (KOSDAQ:127120), A Stock That Climbed 61% In The Last Year

Ripartizione dei ricavi e delle spese

Come DNA Link guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

KOSDAQ:A127120 Ricavi, spese e utili (KRW Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Jun 2419,110-6,9418,75322
31 Mar 2421,046-4,2958,17019
31 Dec 2321,949-5,5968,57485
30 Sep 2318,947-6,4628,700214
30 Jun 2318,718-5,7858,49545
31 Mar 2317,427-5,6317,74166
31 Dec 2216,981-7,7827,141465
30 Sep 2219,141-7,0149,788518
30 Jun 2221,999-5,78610,207700
31 Mar 2223,186-7,52110,770792
31 Dec 2122,992-5,10010,603539
30 Sep 2119,730-9,6217,432635
30 Jun 2116,660-12,3756,862768
31 Mar 2115,903-13,1646,815660
31 Dec 2015,286-13,0676,798464
30 Sep 2015,654-14,56910,185255
30 Jun 2016,208-13,24710,376129
31 Mar 2015,333-12,61610,201354
31 Dec 1915,573-13,1189,955356
30 Sep 1914,397-5,3366,071360
30 Jun 1913,331-5,7136,071343
31 Mar 1914,300-4,9726,012120
31 Dec 1814,876-3,7536,010104
30 Sep 1814,860-2,5505,735411
30 Jun 1815,135-8635,274404
31 Mar 1814,819-234,656411
31 Dec 1714,4803384,076538
30 Sep 1714,888-2,9924,444-74
30 Jun 1714,620-5,7415,046599
31 Mar 1713,206-7,3245,016640
31 Dec 1611,484-9,8115,398585
30 Sep 1610,126-12,9385,5571,809
30 Jun 168,869-11,3414,5611,149
31 Mar 169,396-9,2834,587974
31 Dec 159,420-9,0544,1711,029
30 Sep 159,028-6,0184,20092
30 Jun 159,305-5,3214,235204
31 Dec 148,733-4,4593,412194

Guadagni di qualità: A127120 is currently unprofitable.

Margine di profitto in crescita: A127120 is currently unprofitable.


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: A127120 is unprofitable, but has reduced losses over the past 5 years at a rate of 14.8% per year.

Accelerare la crescita: Unable to compare A127120's earnings growth over the past year to its 5-year average as it is currently unprofitable

Guadagni vs Settore: A127120 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (6.1%).


Rendimento del capitale proprio

ROE elevato: A127120 has a negative Return on Equity (-29.4%), as it is currently unprofitable.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate